# A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

> **NCT03192943** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 11 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** BMS-986205
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03192943
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-23
- **Primary completion:** 2018-12-11
- **Final completion:** 2018-12-11
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2019-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03192943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03192943, "A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03192943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*